CalciMedica Inc.
Chart
Good to know: Investing in stocks tends to provide long-term positive returns, but it also involves risks. You can lose some or all of your investment. Past performance of this stock is not a reliable indicator of future results. Data from external providers has not been altered by Saxo. See full data disclaimer
About CalciMedica Inc.
CalciMedica Inc is a clinical-stage biopharmaceutical company focused on developing therapeutics that treat serious illnesses driven by inflammatory and immunologic processes and direct cellular damage. Its product candidates act upon calcium release-activated calcium (CRAC) channels and would constitute a new class of drugs. Its product candidate is Auxora, a potent and selective intravenous formulated small molecule CRAC channel inhibitor containing the active compound zegocractin (formerly referred to as CM4620) that, in animal models, reduced acute epithelial and/or endothelial cell injury and inflammation in organs, such as the pancreas, lungs and kidneys.
Frequently asked questions
To buy CalciMedica Inc. stock, open a Saxo account and fund it. With SaxoInvestor or SaxoTrader, you can easily search for CalciMedica Inc. by name or ticker, choose the number of shares, and place your order.
The ticker symbol for CalciMedica Inc. is CALC:xnas. You can use this code to quickly find the stock in Saxo’s platforms and track its price and performance.
CalciMedica Inc. has its primary listing on NASDAQ (Small cap). You can trade CalciMedica Inc. with a Saxo account, alongside thousands of other stocks worldwide.
Yes, CalciMedica Inc. is available to trade on SaxoInvestor and SaxoTraderGO. You can buy shares directly and include CalciMedica Inc. as part of a broader investment portfolio. Explore our SaxoInvestor platform.
Learn more about investing and trading at Saxo’s educational content hub. Explore portfolio strategies, types of stocks, diversification, and valuation measures— so you can make more informed decisions when considering shares like CalciMedica Inc..